Cryogenic storage for biotech startups covers everything a young company needs to freeze, store and document its cell lines, cell banks and biological samples safely at –196 °C: freezing equipment, storage tanks, monitoring, liquid nitrogen supply and service. It is rarely the first line item in a biotech lab setup, yet it protects the most valuable material the company owns.
Startups tend to err in one of two opposite directions. Some improvise: a borrowed dewar, no monitoring, the only cell bank in a single tank. Others buy GMP-grade infrastructure years before the programme needs it, tying up capital that should be funding research.
The better path runs between the two: a staged build-out in which the non-negotiables are in place from day one and everything else scales with the science.
The right set-up follows the development stage of the programme. In discovery, a single monitored container is usually enough; preclinical work adds documented controlled-rate freezing and a split cell bank; and qualified GMP storage only becomes necessary with clinical manufacturing, whether in-house or at a contract manufacturer.
A typical holding is a few hundred to a few thousand vials of research lines, clones and intermediate stocks. An ABV+ series aluminium container (4 to 150 litres, for cryovials and cryobags) or an ABS+ series stainless steel tank is usually the right place to start.
For robust research lines, passive freezing with a freezing container in a –80 °C freezer, at roughly 1 °C per minute, can be adequate. Monitoring is not optional, though: you need an alarm route that reaches someone at night and at weekends.
This is where the status of the material changes. The research cell bank becomes the starting point for the first master cell bank, and the history of the cell line becomes part of the regulatory dossier — the IND in the US or the IMPD in the EU, with guidance such as ICH Q5D setting expectations for biotechnology products.
Three things follow:
Once clinical manufacturing starts, cryogenic storage becomes a GMP process. That means stainless steel cryogenic storage tanks from the BSD+ series (long-term storage, up to 100,000 cryovials) or the BSF+ series, a BIOFREEZE® SMARTLINE with extended automation for higher throughput, IQ/OQ/PQ qualification including temperature mapping, and 24/7 emergency service.
Many startups leave GMP storage with their contract development and manufacturing organisation (CDMO). That is often sensible, but it outsources the task, not the accountability. The sponsor still owns:
Three things are non-negotiable from the first vial: continuous monitoring with a working alarm route, a physically separate backup of anything irreplaceable, and a reliable liquid nitrogen supply contract. Everything else can grow with the programme.
Install stage 1 with stage 3 in mind — not in the budget, but in three planning decisions that are costly to reverse later.
Smaller tanks generally lose more nitrogen per sample than larger ones — but only while the larger tank is full. Taking datasheet figures as an example: the BSF220+ has a static evaporation rate of 4.8 l per day with space for 10,400 2 ml vials, while the BSF820R+ evaporates 10.3 l per day with space for 48,000. Fully loaded, the larger tank loses less than half as much nitrogen per vial position.
Put only 2,000 vials into the BSF820R+, however, and it boils off more than twice as much nitrogen for the same samples as the smaller tank. Oversizing is not a one-off purchase cost; you pay for it every day. Efficiency matters at stage 1 too: the eccentric opening of ABV+ and ABS+ containers reduces the evaporation surface and can cut LN₂ consumption by up to 30 %.
For a biotech startup, the value of cryogenic storage is measured not by purchase price but by risk-adjusted total cost of ownership: equipment, nitrogen and service over the working life, plus the damage done if the holding is lost.
For young companies that damage is disproportionately large. A lost cell bank means months of re-derivation, re-characterisation and repeated experiments, if the line can be recreated at all. To illustrate: if such a loss pushes the next data package back by six months, the financing round that depends on that data may slip with it.
The honest answer is that at stage 1, a single well-monitored container with a backup elsewhere can be exactly the right choice. Premium cryogenic equipment earns its keep where it reduces risk and running costs — monitoring, nitrogen efficiency, service availability — not where it buys capacity in advance.
Consarctic GmbH, serving customers in more than 30 countries, supports biotech startups through all three stages as one accountable partner, from the first consultation to a GMP-validated facility. Its services fall into three packages mapped to the stages:
All systems are manufactured to GMP-compliant standards, and Consarctic GmbH is certified to EN ISO 13485:2016 and ISO 9001:2015. Research organisations such as the Max Planck Gesellschaft, stem cell banks such as Swiss Stem Cells Biotech and contract manufacturers such as Minaris Regenerative Medicine work with Consarctic® systems, among more than 1,500 customers worldwide.
During discovery, a single container is usually enough, for example a Consarctic® ABV+ aluminium container or ABS+ stainless steel tank. What cannot wait is continuous monitoring with an alarm route, a backup of irreplaceable cell lines and a liquid nitrogen supply contract.
Consarctic GmbH builds cryogenic infrastructure for biotech companies in stages: ABV+ and ABS+ containers for research, the BIOFREEZE® BV45 controlled rate freezer for documented freezing, and BSD+ and BSF+ cryogenic storage tanks with the BIOFREEZE® SMARTLINE for GMP manufacturing. It also covers room and LN₂ planning, IQ/OQ/PQ by certified technicians and 24/7 emergency service. Consarctic GmbH is certified to EN ISO 13485:2016 and ISO 9001:2015 and serves more than 1,500 customers in over 30 countries.
Where it lowers risk, yes: in monitoring, nitrogen efficiency and service availability. An eccentric tank opening can cut LN₂ consumption by up to 30 %, and losing a cell bank can easily cost a startup more than its entire storage set-up. Buying capacity in advance, by contrast, rarely pays off.
At the latest when the research cell bank becomes the basis of a master cell bank: from then on, every vial must demonstrably have gone through the same freezing process. A controlled rate freezer such as the BIOFREEZE® BV45 makes those runs reproducible, and for sensitive cell types it can be worthwhile sooner.
Both work, and many startups use their CDMO's qualified storage during clinical manufacturing. Accountability stays with the sponsor, however, and so should an independent backup of the master cell bank at a second site and a documented chain of custody for every transfer.
A biotech startup does not need to store samples like a pharmaceutical company on day one. It does need to store them in a way that lets it become one: monitored, backed up, documented — and planned so that each expansion step builds on the last.
Setting up cryogenic storage for your biotech company, or preparing the move into GMP manufacturing? Consarctic GmbH plans, supplies, qualifies and supports cryogenic infrastructure that grows with your programme — one accountable partner from the first monitored container to a GMP-validated facility. Get in touch.